Drug
IT-101 clinical trials
Also written CRLX101 and NLG207.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
NewLink Genetics Corporation (5) · Ellipses Pharma (2) · National Cancer Institute (NCI) (2) · Abramson Cancer Center at Penn Medicine (1) · Massachusetts General Hospital (1) · City of Hope Medical Center (1) · University of Chicago (1)
Often tested with
Tested in the same studies.
Olaparib (3) · Bevacizumab (2) · Paclitaxel (1) · Enzalutamide (1)
Studies
Open first, then newest update. How each study uses IT-101 is read from its arms, and is right about nine times in ten.
Testing it · 13
- Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT02769962Written as EP0057
- A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedPhase 1/2NewLink Genetics CorporationNCT02389985Written as CRLX101
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedPhase 2Ellipses PharmaNCT04669002Written as EP0057
- EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnPhase 2Ellipses PharmaNCT05411679Written as EP0057
- Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTerminatedPhase 2National Cancer Institute (NCI)NCT03531827Written as CRLX101
- Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung CancerTerminatedPhase 2University of ChicagoNCT01803269Written as cyclodextrin-based polymer-camptothecin CRLX101
- Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.WithdrawnPhase 2NewLink Genetics CorporationNCT00753740Written as IT-101 (12mg/m2/dose)
- A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2NewLink Genetics CorporationNCT01380769Written as CRLX101
- Study of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsCompletedPhase 1/2NewLink Genetics CorporationNCT00333502Written as Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)CompletedPhase 2NewLink Genetics CorporationNCT02187302Written as CRLX101
- CRLX101 Plus Bevacizumab in Advanced RCCCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01625936Written as CRLX101 (Cerulean)
- CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal CancerCompletedPhase 2Massachusetts General HospitalNCT01652079Written as CRLX101
- Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by SurgeryCompletedPhase 2City of Hope Medical CenterNCT01612546Written as cyclodextrin-based polymer-camptothecin CRLX101
Given in every arm · 2 — IT-101 is usual care beside what is tested
- Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal CancerTerminatedPhase 1/2UNC Lineberger Comprehensive Cancer CenterNCT02010567Written as CRLX101
- Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsTerminatedPhase 1NewLink Genetics CorporationNCT02648711Written as CRLX101